Combined 68Ga-PSMA PET/CT and mpMRI Findings Improve Tumor Localization and Biopsy Guidance in the Initial Diagnosis of Prostate Cancer
PDF
Cite
Share
Request
Interesting Image
VOLUME: 34 ISSUE: 2
P: 146 - 148
June 2025

Combined 68Ga-PSMA PET/CT and mpMRI Findings Improve Tumor Localization and Biopsy Guidance in the Initial Diagnosis of Prostate Cancer

Mol Imaging Radionucl Ther 2025;34(2):146-148
1. University Hospital Alexandrovska, Clinic of Nuclear Medicine, Sofia, Bulgaria
2. University Hospital Alexandrovska, Clinic of Urology, Sofia, Bulgaria
3. Medical Institute of the Ministry of Interior, Clinic of Urology, Sofia, Bulgaria
No information available.
No information available
Received Date: 16.07.2024
Accepted Date: 08.09.2024
Online Date: 03.06.2025
Publish Date: 03.06.2025
PDF
Cite
Share
Request

Abstract

Gallium-68 (68Ga)-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is a relatively new imaging modality that has already proved its role in the initial staging of prostate cancer and in biochemical recurrence following definitive primary therapy. Furthermore, emerging data several ongoing studies demonstrate its potential role in the primary diagnosis of this malignancy. We present a 67-year-old male patient with increasing clinical suspicion of prostate cancer despite a previous negative prostate gland biopsy. He was referred to our nuclear medicine department for a 68Ga-PSMA PET/CT with the aim of improving tumor localization and assisting in the guidance of repeat prostate biopsy. One month before presentation of elevated prostate-specific antigen levels, he underwent multiparametric magnetic resonance imaging (mpMRI), which revealed a prostate imaging reporting and data system 4 lesion in the right lobe of the prostate gland. The MRI lesion completely matched a PRIMARY score 5 lesion registered by PET/CT. Furthermore, we detected another suspicious finding in the left lobe (PRIMARY score 4). The patient underwent PSMA PET/CT-guided MRI/ultrasonography fusion transperineal biopsy of both lesions. The latter were histologically confirmed as prostate carcinoma with a Gleason score of 3+4 =7.

Keywords:
68Ga-PSMA PET/CT, mpMRI, initial diagnosis of prostate cancer

Ethics

Informed Consent: The patient consent was obtained.

Authorship Contributions

Surgical and Medical Practices: Y.G., V.Y., N.H., Concept: Y.G., P.N., Design: Y.G., M.I., V.Y., Data Collection or Processing: Y.G., V.Y., Analysis or Interpretation: Y.G., P.N., Literature Search: Y.G., V.H., Writing: Y.G., M.I., V.H.
Conflict of Interest: No conflicts of interest were declared by the authors.
Financial Disclosure: The authors declare that this study has received no financial support.

References

1
Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, Thompson J, Moon D, Sheehan-Dare G, Alghazo O, Agrawal S, Murphy D, Stricker P, Hope TA, Hofman MS. The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis. J Nucl Med. 2022;63:1644-1650.
2
Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Schöder H, Wan S, Wester HJ, Hope TA, Herrmann K. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466-1486.
3
EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6.